Ovid reports Q3 2026 updates on OV329 and OV4071 epilepsy, psychosis programs

Ovid Therapeutics provided business updates and third quarter 2026 financial results on November 10, 2026. The company's Phase 2 global, randomized placebo-controlled study of OV329 in treatment-resistant focal epilepsy is actively enrolling at a 7 mg dose, is designed with registrational-level rigor, and is anticipated to be completed in the second half of 2027.¹

A separate photo paroxysmal response study testing OV329's anticonvulsant effect at 7 mg, with additional doses above and below, is enrolling, with topline data expected in the first quarter of 2027.¹

A safety and signal-finding study in TSC-associated seizures is on track for initiation in the fourth quarter of 2026, with regulatory clearances in process; the open-label trial is also meant to confirm pharmacology and dosing for younger pediatric patients.¹ Ovid plans a safety and signal-finding study of OV329 in infantile spasms in 2027, following several cohorts of the TSC study.¹

For OV4071, described as Ovid's oral, clinical stage direct activator of KCC2,¹ the company is running a Phase 1 single- and multiple-ascending dose study in healthy volunteers with no serious adverse events reported to date, with topline data expected in the first quarter of 2027.¹ A translational ketamine challenge study of OV4071 is ready for initiation with results expected in the first quarter of 2027, and the company has a first planned Phase 2 study in acute schizophrenia set for 2027.¹

On corporate matters, Ovid and Takeda assigned global rights in soticlestat to a new company launched by Perceptive Advisors, under which Ovid is eligible for up to $294.5 million in milestone payments, part of which is payable to Ligand Pharmaceuticals, plus potential royalties.¹

Cash, cash equivalents and marketable securities totaled $161.4 million as of September 30, 2026.¹ The company said this is expected to fund operations into 2029.